UNICANCER
- Country
- 🇧🇷Brazil
- Ownership
- Private
- Established
- 1964-01-01
- Employees
- 101
- Market Cap
- -
- Website
- http://www.unicancer.fr
A Phase III Study for Patients With Metastatic Hormone-naïve Prostate Cancer
- Conditions
- Interventions
- First Posted Date
- 2013-10-08
- Last Posted Date
- 2024-11-11
- Lead Sponsor
- UNICANCER
- Target Recruit Count
- 1173
- Registration Number
- NCT01957436
- Locations
- 🇪🇸
Hospital Germans Trias i Pujol, Badalona, Spain
🇪🇸Vall d'Hebron University Hospital, Barcelona, Spain
🇪🇸ICO Girona - Hospital Josep Trueta, Girona, Spain
A Phase III of Cabazitaxel and Pelvic Radiotherapy in Localized Prostate Cancer and High-risk Features of Relapse
- Conditions
- Interventions
- First Posted Date
- 2013-09-27
- Last Posted Date
- 2024-04-09
- Lead Sponsor
- UNICANCER
- Target Recruit Count
- 761
- Registration Number
- NCT01952223
- Locations
- 🇫🇷
Institut Gustave Roussy, Villejuif, France
Dual Targeting of EGFR With Cetuximab and Afatinib to Treat Refractory wtKRAS Metastatic Colorectal Cancer
- Conditions
- Interventions
- First Posted Date
- 2013-08-09
- Last Posted Date
- 2018-05-08
- Lead Sponsor
- UNICANCER
- Target Recruit Count
- 75
- Registration Number
- NCT01919879
- Locations
- 🇫🇷
Institute de Cancérologie de la Loire, Nantes, France
Abiraterone Acetate in Molecular Apocrine Breast Cancer
- First Posted Date
- 2013-04-29
- Last Posted Date
- 2021-02-23
- Lead Sponsor
- UNICANCER
- Target Recruit Count
- 34
- Registration Number
- NCT01842321
- Locations
- 🇫🇷
Centre Georges-François Leclerc, Dijon, France
🇫🇷Chu de Brest - Hôpital Morvan, Brest, France
🇫🇷Ico - Site Paul Papin, Angers, France
Safety Study of Adding Everolimus to Adjuvant Hormone Therapy in Women With High Risk of Relapse, ER+ and HER2- Primary Breast Cancer, Free of Disease After Receiving at Least One Year of Adjuvant Hormone Therapy
- Conditions
- Interventions
- First Posted Date
- 2013-03-06
- Last Posted Date
- 2024-04-10
- Lead Sponsor
- UNICANCER
- Target Recruit Count
- 1278
- Registration Number
- NCT01805271
- Locations
- 🇫🇷
Centre Leon Berard, Lyon, France
🇫🇷Gustave Roussy, Villejuif, France
Efficacy of Neoadjuvant Folfirinox Regimen in Patients With Resectable Locally Advanced Rectal Cancer
- Conditions
- Interventions
- First Posted Date
- 2013-03-05
- Last Posted Date
- 2024-09-30
- Lead Sponsor
- UNICANCER
- Target Recruit Count
- 461
- Registration Number
- NCT01804790
- Locations
- 🇫🇷
Gustave Roussy, Villejuif, France
🇫🇷ICO - Site Paul Papin, Angers, France
🇫🇷Centre hospitalier Universitaire d'Amiens, Amiens, France
Radiotherapy Plus Hormone Therapy in Biochemically-relapsing Prostate Cancer Patients Following Surgery
- Conditions
- Interventions
- First Posted Date
- 2013-01-30
- Last Posted Date
- 2022-05-19
- Lead Sponsor
- UNICANCER
- Target Recruit Count
- 47
- Registration Number
- NCT01780220
- Locations
- 🇫🇷
Centre François Baclesse, Caen, France
🇫🇷Institut de Cancérologie de l'ouest/René Gauducheau, Saint-Herblain, France
🇫🇷Centre Leon Berard, Lyon, France
Cohort Study of Prospective Validation of Predictive Factors and Biological Imaging of Response to Bevacizumab and Paclitaxel in Patients With Metastatic Breast Cancer
- First Posted Date
- 2012-12-10
- Last Posted Date
- 2023-01-27
- Lead Sponsor
- UNICANCER
- Target Recruit Count
- 510
- Registration Number
- NCT01745757
- Locations
- 🇫🇷
Hôpital Européen, Marseille, France
🇫🇷Centre Hospitalier, Roanne, France
🇫🇷Centre Paul Strauss, Strasbourg, France
A Phase II, Open-Label, Multicenter Trial of Cabazitaxel in Patients With Recurrent or Metastatic Head and Neck Cancer After Failure Of Cisplatin, Cetuximab and Taxanes
- Conditions
- Interventions
- First Posted Date
- 2012-06-15
- Last Posted Date
- 2021-03-02
- Lead Sponsor
- UNICANCER
- Target Recruit Count
- 31
- Registration Number
- NCT01620242
- Locations
- 🇫🇷
Centre Oscar Lambret, Lille, France
🇫🇷Centre Léon Berard, Lyon, France
🇫🇷Centre Antoine Lacassagne, Nice, France
Adjuvant Systemic Treatment for (ER)-Positive HER2-negative Breast Carcinoma in Women Over 70 According to Genomic Grade (GG): Chemotherapy + Endocrine Treatment Versus Endocrine Treatment
- Conditions
- Interventions
- First Posted Date
- 2012-03-27
- Last Posted Date
- 2024-05-17
- Lead Sponsor
- UNICANCER
- Target Recruit Count
- 1989
- Registration Number
- NCT01564056
- Locations
- 🇫🇷
Centre Jean Perrin, Clermont Ferrand, France
🇧🇪Grand Hopital de Charleroi (GHdC), Charleroi, Belgium
🇧🇪CHU Ambroise Paré, Mons, Belgium